Search Within

Genitourinary Oncology Service

  1. "British Journal of Cancer"
Formats
  1. Journal Article (27)
  2. Guidelines (1)
Groups
  1. Department of Medicine (28)
  2. Solid Tumor Oncology Division (28)
  3. Surgery (4)
  4. Urology (4)
  5. Survivorship Research (3)
  6. Biostatistics Service (2)

More Groups

People
  1. Robert Motzer (16)
  2. Howard Scher (4)
  3. Martin Voss (4)
  4. Chung-Han Lee (3)
  5. Jonathan Rosenberg (3)
  6. Dana Rathkopf (2)

More People

Years
  1. 2024 (1)
  2. 2021 (2)
  3. 2020 (2)
  4. 2018 (6)
  5. 2016 (1)
  6. 2015 (3)

More Years

Publications
  1. British Journal of Cancer (28)
Publishers
  1. Nature Publishing Group (28)

Results (28)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Phase 1b study of enzalutamide plus CC-115, a dual mTORC1/2 and DNA-PK inhibitor, in men with metastatic castration-resistant prostate cancer (mCRPC)
    Journal Article

    Zhao, J. L.; Antonarakis, E. S.; Cheng, H. H.; George, D. J.; Aggarwal, R.; Riedel, E.; Sumiyoshi, T.; Schonhoft, J. D.; Anderson, A.; Mao, N.; more...
    British Journal of Cancer (2024)

    Fulltext@MSK | Save
  • Natural history, response to systemic therapy, and genomic landscape of plasmacytoid urothelial carcinoma
    Journal Article

    Teo, M. Y.; Al-Ahmadie, H.; Seier, K.; Tully, C.; Regazzi, A. M.; Pietzak, E.; Solit, D. B.; Tickoo, S.; Reuter, V.; Cha, E. K.; more...
    British Journal of Cancer (2021)

    Fulltext@MSK | Save
  • Correlative serum biomarker analyses in the phase 2 trial of lenvatinib-plus-everolimus in patients with metastatic renal cell carcinoma
    Journal Article

    Lee, C. H.; Motzer, R. J.; Glen, H.; Michaelson, M. D.; Larkin, J.; Minoshima, Y.; Kanekiyo, M.; Ikezawa, H.; Sachdev, P.; Dutcus, C. E.; more...
    British Journal of Cancer (2021)

    Fulltext@MSK | Save
  • Phase 1 study of mTORC1/2 inhibitor sapanisertib (TAK-228) in advanced solid tumours, with an expansion phase in renal, endometrial or bladder cancer
    Journal Article

    Voss, M. H.; Gordon, M. S.; Mita, M.; Rini, B.; Makker, V.; Macarulla, T.; Smith, D. C.; Cervantes, A.; Puzanov, I.; Pili, R.; more...
    British Journal of Cancer (2020)

    Fulltext@MSK | Save
  • Axitinib plus immune checkpoint inhibitor: Evidence- and expert-based consensus recommendation for treatment optimisation and management of related adverse events
    Guidelines

    Grünwald, V.; Voss, M. H.; Rini, B. I.; Powles, T.; Albiges, L.; Giles, R. H.; Jonasch, E.
    British Journal of Cancer (2020)

    Fulltext@MSK | Save
  • Combination VEGFR/immune checkpoint inhibitor therapy: A promising new treatment for renal cell carcinoma
    Journal Article

    Lee, C. H.; Motzer, R.
    British Journal of Cancer (2018)

    Fulltext@MSK | Save
  • Lessons from the SWITCH trial: Changing glucocorticoids in the management of metastatic castration-resistant prostate cancer (mCRPC)
    Journal Article

    Teo, M. Y.; Scher, H. I.
    British Journal of Cancer (2018)

    Fulltext@MSK | Save
  • Outcomes based on prior therapy in the phase 3 METEOR trial of cabozantinib versus everolimus in advanced renal cell carcinoma
    Journal Article

    Powles, T.; Motzer, R. J.; Escudier, B.; Pal, S.; Kollmannsberger, C.; Pikiel, J.; Gurney, H.; Rha, S. Y.; Park, S. H.; Geertsen, P. F.; more...
    British Journal of Cancer (2018)

    Fulltext@MSK | Save
  • Everolimus and pazopanib (E/P) benefit genomically selected patients with metastatic urothelial carcinoma
    Journal Article

    Bellmunt, J.; Lalani, A. K. A.; Jacobus, S.; Wankowicz, S. A.; Polacek, L.; Takeda, D. Y.; Harshman, L. C.; Wagle, N.; Moreno, I.; Lundgren, K.; more...
    British Journal of Cancer (2018)

    Fulltext@MSK | Save
  • Apatorsen plus docetaxel versus docetaxel alone in platinum-resistant metastatic urothelial carcinoma (Borealis-2)
    Journal Article

    Rosenberg, J. E.; Hahn, N. M.; Regan, M. M.; Werner, L.; Alva, A.; George, S.; Picus, J.; Alter, R.; Balar, A.; Hoffman-Censits, J.; more...
    British Journal of Cancer (2018)

    Fulltext@MSK | Save